{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Grade/description', 'Toxicity', 'Recommendations for GSK2857916', 'of toxicity', 'medication, and extension of infusion time to 2-4 hours.', 'Any future infusion needs to be pre-medicated', '4', 'Permanently discontinue', '2', 'Continue treatment when toxicity resolves to Grade 0-1', 'Pneumonitis', 'Grade 3-4', 'Permanently discontinue', 'a.', \"Medical Monitor may consult GSK's nephrotoxicity panel about plans to continue therapy.\", 'b.', 'If symptoms resolve within one hour of stopping infusion, the infusion may be restarted at 50% of the original', 'infusion rate (e.g., from 100 mL/hr. to 50 mL/hr.). Otherwise dosing will be held until symptoms resolve and the', 'participant must be pre-medicated for the next scheduled dose.', 'Table 12', 'General Dose Modification and Management Guidelines for Drug-', 'related Adverse Events Not Otherwise Specifieda', 'Severity', 'Management', 'Follow-up', 'Administer symptomatic', 'Grade 1', 'Provide close follow-up to evaluate for increased severity,', 'treatment as appropriate', 'no dose modification necessary', 'Continue study drug(s)a', 'Administer symptomatic', 'Symptoms resolved in 7 days:', 'Continue after resolution at the current dose', 'treatment', 'Symptoms ongoing >7 days or worsening:', 'Grade 2', 'Investigate etiology', 'Delay study drugb, or consider dose reduction by', 'Consider consulting', '25% If recovery takes >3 weeks- consult GSK MM', 'subspecialist, and/or', 'If symptoms continue or worsen to Grade 3-4, see', 'diagnostic procedure', 'below', 'Delay treatment till recovery to G1 or less. Consider dose', 'Provide appropriate medical', 'reduction. Consider consultation with GSK MM.', 'treatment', 'Grade 3', 'Exceptions: Participants who develop G3 toxicities which', 'Consider Consulting', 'respond to standard treatment and resolve to <G1 within 48', 'subspecialist', 'hours may continue treatment at scheduled or reduced', 'dose', 'Provide appropriate medical', 'treatment', 'Interrupt treatment. Further treatment with GSK2857916', 'Grade 4', 'Consider Consulting', 'only allowed on individual basis if in the discussion with MM', 'subspecialist', 'it is agreed that benefits outweigh the risks for a given', 'Discuss with', 'participant', 'Sponsor/Medical Monitor', 'a.', 'Treatment-related decisions can be made based on local laboratory results if central results are not available or', 'delayed.', 'b. In case a dose is delayed, the participant should wait for the next scheduled dose to resume treatment.', '60']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 13', 'Dose Modification Guidelines for GSK2857916 Treatment-Related', 'Corneal Events', 'Grade 1 per', 'Grade 2 per GSK', 'Grade 3 per GSK', 'Grade 4 per GSK', 'GSK Scale', 'Scale', 'Scale', 'Scale', 'GSK2857916', 'Continue', 'If either', 'Hold GSK2857916', 'Stop treatment with', 'Dosing', 'treatment with', 'ophthalmic exam', 'GSK2857916.', 'Actions', 'current dose', 'Upon', 'findings or visual', 'of', 'improvement of', 'Additional topical', 'acuity findings are', 'GSK2857916.', 'Grade 1, continue', 'either visual acuity', 'treatment may be', 'or ophthalmic', 'prescribed, as', 'dosing with', 'GSK2857916 at', 'exam findings to', 'recommended by', 'Grade 1 or', 'ophthalmologist*', 'current dose.', 'baseline, resume', 'with 25% dose', 'reduction*', 'Treatment re-start', 'If visual acuity', 'may be possible', 'and exam', '(* for participants', 'after discussion and', 'findings are both', 'receiving 1.92', 'agreement between', 'Grade 2, HOLD', 'mg/kg dose-', 'the treating', 'GSK2857916.', 'continue at 1.92', 'ophthalmologist*,', 'Upon', 'mg/kg)', 'treating physician,', 'improvement', 'the GSK Medical', 'of either visual', 'In case of recurring', 'Monitor and possibly', 'acuity or', 'a GSK', '>Gr3 events, consult', 'ophthalmic', 'GSK Medical', 'ophthalmologist', 'exam findings', 'monitor', '*or optometrist, if an', 'to Grade 1 or', 'ophthalmologist is', 'baseline,', 'not available', 'resume with', 'current dose', 'Corneal', 'Steroid Eye Drops:', 'Management', 'Care', 'If symptoms occur within the 7-day steroid eye drop prophylaxis window,', 'increase the frequency to 1 drop every 2-4 hours (6-12 times daily) and', 'Regardless', 'of Gradeb', 'continue until symptom resolution.', 'If symptoms occur after the 7-day prophylaxis window is complete, re-start', 'ocular steroid drops at 4x daily until symptom resolution.', 'Preservative-free artificial tears:', 'Increase to 1 drop as frequently as every 2 hours, as needed', 'a.', 'See Appendix 9 for GSK Scale for GSK2857916 Corneal Events', 'b.', 'In the sub-study of approximately 30 participants will receive monocular topical corticosteroids for the first 4', 'cycles, (or every 3 weeks in the case of dose delays) treatment of both eyes (in case of worsening', 'symptoms in the untreated eye) with topical corticosteroids will be at the discretion of the Investigator.', '61']\n\n###\n\n", "completion": "END"}